Wednesday, March 23, 2016 | |||
8:30 am - 9:45 am | Plenary Session 9: Drug Development Methodology Chair: Jean-Charles Soria, Cancer Institute Gustave Roussy Chair: Lee Ellis, MD Anderson Cancer Center | ||
8:31 am - 8:50 am | O9.1 Exosomal DNA in serum for cancer diagnosis and detection of gene mutations Speaker: Christoph Kahlert, Technical University Dresden | ||
8:50 am - 9:10 am | O9.2 Circulating cells and cell-free nucleic acids in cancer treatment monitoring Speaker: Anton Wellstein, Georgetown University Medical School | ||
9:10 am - 9:30 am | O9.3 Value of patient-derived xenografts and organoids in therapy selection Speaker: Manuel Hidalgo, Spanish National Cancer Research Centre | ||
9:30 am - 9:45 am | General discussion | ||
9:45 am - 10:15 am | Break |
10:15 am - 12:15 pm | Plenary Session 10: Miscellaneous Drugs and Targets (1) Chair: Anthony Tolcher, South Texas Accelerated Research Therapeutics Chair: Keith Flaherty, Massachusetts General Hospital |
10:16 am - 10:30 am | O10.1 A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors Speaker: Emiliano Calvo, START Madrid |
10:30 am - 10:45 am | O10.2 Merging the concepts of compensatory signaling and epigenetic state change in therapeutic resistance Speaker: Keith Flaherty, Massachusetts General Hospital |
10:45 am - 11:00 am | O10.3 Inhibiting mutant isocitrate dehydrogenase: Triumphs and challenges Speaker: Eytan Stein, Memorial Sloan Kettering Cancer Center |
11:00 am - 11:15 am | O10.4 Phase 1 trial of a first-in-class PFKFB3 inhibitor reveals a novel immunostimulatory mechanism of action Speaker: Jason Chesney, University of Louisville |
11:15 am - 11:30 am | O10.5 Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 Speaker: Manish Patel, Florida Cancer Specialists/SCRI |
11:30 am - 11:45 am | O10.6 Glutaminase inhibition by CB-839 (Calithera) Speaker: James Harding, Memorial Sloan Kettering Cancer Center |
11:45 am - 12:15 pm | General discussion |
12:15 pm - 1:00 pm | Lunch |
1:00 pm - 3:00 pm | Plenary Session 11: Miscellaneous Drugs and Targets (2) Chair: Udai Banerji, The Institute of Cancer Research Chair: Arne Östman, Karolinska Institutet |
1:01 pm - 1:20 pm | O11.1 Targeting Sleeping Cancer Cells Speaker: Sridhar Ramaswamy, Massachusetts General Hospital |
1:20 pm - 1:45 pm | O11.2 Clinical Implications of Intratumour Heterogeneity Speaker: Charles Swanton, The Francis Crick Institute |
1:45 pm - 2:05 pm | O11.3 Nuclear export as a target for cancer therapy Speaker: Giuseppe Giaccone, Georgetown University |
2:05 pm - 2:20 pm | O11.4 PROTAC BRD4 Degraders Allow a More Effective Therapeutic Strategy than BRD4 Inhibitors Speaker: James Winkler, Arvinas |
2:20 pm - 2:35 pm | O11.5 The rich molecular landscape of metastatic biliary tract cancers in the MOSCATO 01 prospective trial Speaker: Loic Verlingue, Cancer Institute Gustave Roussy |
2:35 pm - 2:50 pm | O11.6 Novel targeted phosphorylated p68 inhibitor RX-5902 shows activity in triple negative breast cancer Speaker: Jennifer Diamond, University of Colorado Cancer Center |
2:50 pm - 3:05 pm | General discussion |
3:05 pm - 3:10 pm | Closing remarks Giuseppe Giaccone, Georgetown University |